XML 44 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Additions and Returns of Product Rights (Tables)
 9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Schedule of Business Acquisitions by Acquisition, Contingent Consideration The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis. The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
Balance at December 31, 2020
$8,200,552 
Cash payment of royalty during the period(1,792,573)
Change in fair value of contingent consideration included in operating expenses(632,646)
Contingent consideration earned and accrued in operating expenses1,134,333 
Balance at September 30, 2021
$6,909,666 
Schedule of Dissolution Payments
The dissolution payments from Clinigen are reflected as revenue from discontinued operations. The Company does not incur expenses associated with these payments from Clinigen.
Three months ended September 30,Nine months ended September 30,
2021202020212020
Revenues$496,787 $777,916 $1,491,004 $2,334,811 
Costs of products sold— — — — 
Selling, Marketing and other— — — — 
Income from discontinued operations$496,787 $777,916 $1,491,004 $2,334,811